Optimising Renal Care

Optimising Care Series 2020

A/Prof David Gracey

Royal Prince Alfred Hospital, University of Sydney

Outline – Optimising Renal Care

- Case discussion
 - What would you do?

- Measurement of renal function
- AKI vs. CKD vs. ESRF
 - What are they?
- Managing CKD
 - When to refer
 - What to do about proteinuria

Q1: How comfortable are you managing patients with chronic kidney disease?

- 1. Not at all comfortable
- 2. I rarely do, and try to avoid it
- 3. Somewhat comfortable
- 4. Comfortable
- 5. Very comfortable

Case Study

- 52 year old. From the Philippines
- Recently diagnosed HIV and commenced on ART + Resprim for PJP prophylaxis 3 months earlier. CD4 90. VL now UD
- Medications:
 - Descovy 200/25
 - Raltegravir bd
 - Metformin
 - Resprim half daily

- PMH
 - Diabetes
 - Anxiety
 - Previous heavy ETOH and IVDU
 - Hypertension: stopped taking tablets ~3 years ago

- Investigations:
 - serum creatinine 205µmol/L (normal <90µmol/L)
 - U/A Protein+++ no blood

Q2: What is the renal diagnosis?

- 1. Acute Kidney Injury from Resprim
- 2. Acute Kidney Injury secondary to ART-induced nephrotoxicity
- 3. Acute Kidney Injury related to immune reconstitution inflammatory syndrome
- 4. Acute kidney Injury on a background of chronic kidney disease
- 5. Chronic kidney disease secondary to diabetes



Stages of kidney disease



- 5 eGFR <15
- 4 eGFR 30-15
- 3 eGFR 60-30
- 2 eGFR 90-60
- 1 eGFR >90 markers of damage



Are you at increased risk?







Heart problems Family history



Obesity

Smoker

Aboriginal or Torres 60 years Strait Islander or older

History of acute kidney injury

#KHW17 #kidneysfirst

The Kidney Check

- Should be performed in 'at risk' patients at least annually
- Risk factors for kidney disease very similar to heart disease (+ FHx, AKI, nephrotoxic Rx)
- Earlier detection of CKD results in better outcomes
- Clinically:
 - Blood pressure
 - uACR and U/A (blood and protein)
 - eGFR

Measuring renal function

- eGFR calculated automatically from serum creatinine (adjusted for age and sex)
 - Remember renal function declines with age (~1ml/min/year after 35yo)
- Creatinine is a breakdown product of muscle metabolism. More muscle = higher creatinine, Less muscle = lower creatinine
- Dietary intake, protein powders, supplements and bone broth soups
- Extremes of BMI, racial differences
- Medications can interfere with serum creatinine (Resprim, COBI)
 - actual vs. estimated GFR

COBI and TDF - Effect On Creatinine Tubular Secretion

• TDF undergoes active tubular secretion with uptake via OAT1/OAT3 and secretion by MRP4. COBI does not inhibit these transporters¹⁻³



German P, et al. *J Acquir Immune Defic Syndr*. 2012;61:32-40. ² Lepist EI, Ray AS. *Expert Opin Drug Metab Toxicol*. 2012;8:433-448. ³ Lepist EI, et al. ICAAC 2011; abstract A1-1724.

Case continued...

- In order to answer my first question we needed more information:
- What was her baseline renal function? (creatinine 12 months before 188µmol/L, eGFR 26 – at first review eGFR 24)
- Acute vs. Chronic vs. Acute-on-chronic

Our patient was at high renal and cardiovascular risk

- Diabetes, hypertension, smoker, HIV, non-compliance, previous IVDU (HCVassociated renal disease?), proteinuria, established CKD; advanced and progressive
- Need to intervene stringently and aggressively on modifiable risk factors to prevent progression

Q3: The most important aspect of managing our patient is:

- 1. Improving diabetic control
- 2. Blood pressure management
- 3. Modifying ART
- 4. Smoking cessation
- 5. Referral to a renal physician

Comorbidities: Aquitaine Cohort

- High rate of comorbidities in 2004, significantly increased by 2014
- Dyslipidaemia (+40.2%) and hypertension (+37.5%). Chronic kidney disease (+14.7%) and cardiovascular events (+10.4%)



Modelling: Intervention and change in CVD/renal risk

• INTENSIFIED MONITORING AND DRUG TREATMENT OF HYPERTENSION AND DYSLIPIDAEMIA WILL PREVENT 17–20% OF CVD CASES ANNUALLY



© 2018 British HIV Association D0I: 10.1111/hiv.12637 HIV Medicine (2018), 19, 5–23 ORIGINAL RESEARCH

HIV in practice: current approaches and challenges in the diagnosis, treatment and management of HIV infection in Australia

DE Smith,^{1,2} IJ Woolley,^{3,4} DB Russell,^{5,6} F Bisshop⁷ and V Furner¹

- Development of comorbidities was the commonest reason for switching ARVs
- Managing comorbidities the second most commonly identified critical challenge facing PLWH in Australia

Non-AIDS complexity amongst patients living with HIV in Sydney: risk factors and health outcomes

```
Derek J Chan <sup>1</sup> <sup>2</sup>, Virginia Furner <sup>1</sup>, Don E Smith <sup>3</sup> <sup>4</sup>, Mithilesh Dronavalli <sup>1</sup>, Rohan I Bopage <sup>1</sup> <sup>2</sup>, Jeffrey J Post <sup>1</sup> <sup>5</sup> <sup>6</sup>, Anjali K Bhardwaj <sup>7</sup>
```

- At Albion Centre, publically funded HIV clinic in central Sydney
- 50% no GP
- 25% no Medicare
- CVD 25%, 20% diabetes
- 50% Hx cigarette smoking

RESEARCH ARTICLE

The prevalence and risk of non-infectious comorbidities in HIV-infected and non-HIV infected men attending general practice in Australia

Jack Edward Heron^{1‡}, Sarah M. Norman^{2‡}, Jeannie Yoo², Kirsty Lembke², Catherine C. O'Connor^{3,4}, Clare E. Weston²*, David M. Gracey¹



O PLOS ONE

Measurement of proteinuria

- Urobilinogen • Dipstix urinalysis: detects albumin, not other proteins. Does not detect <300mg protein / day. Other inclusions can be useful ProteIn
- uACR: detects urinary albumin down to a very low level. **Recommended for screening for CKD**
 - 'albuminuria' vs 'proteinuria'
- uPCR: detects proteins other than albumin (can be useful with 'tubular' proteinuria and TDF)
- 24 hour urinary protein excretion: cumbersome, sometimes usef



120s

Nitrite 60s

60s

60s

pН

60s

Blood 60s

45s

Ketone 40s

Billrubin 30s

Glucose 30s

Modifying renal risk – proteinuria

- Consider what is the cause? Need for further Ix (refer) ?
- Reducing blood pressure reduces amount of proteinuria
- Preferentially use anti-hypertensive agents with additional antiproteinuric effects: ACE-inhibitors and ARBs
- Use cautiously in people with CKD (K+ and worsening of CKD)
- Be careful if on other medications which may increase K+ (aldactone, avoid NSAIDs)
- SGLT-2 inhibitors: effect in reducing proteinuria and improving renal survival is even greater than ACEi/ARB in selected patients
- Diet: not too high in protein

SGLT-2 inhibitors and diabetic CKD

Explosion of recent evidence – more and more publications every week

- For selected patients
- Reno-protective and cardioprotective
- Reduces proteinuria
- Benefit > ACEi
- Will result in glycosuria
- Can worsen renal function
 - Not in advanced CKD

Good for non diabetic CKD? Slows progression

CLINICAL RESEARCH www.jasn.org

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Alexia Piperidou^a, Pantelis Sarafidis^b, Afroditi Boutou^c, Costas Thomopoulos^d, Charalampos Loutradis^b, Maria Eleni Alexandrou^e, Apostolos Tsapas^f, and Asterios Karagiannis^a

Modifying renal risk - Hypertension

- In the presence of CKD aim for BP<130/80
- Lifestyle factors important. Reduce salt diet. Weight loss.
- Start with ACEi/ARB, especially if proteinuria/diabetes
- Monitor creatinine and K+ both may go up a little
- If diabetic not on ACE, but on something else ? switch
- Maximise dose of ARB/ACE first, but may need to add more than one agent; second line ?CCB ?β-blocker ?diuretic
- If resistant or difficult to control, refer.

Modifying renal risk – Diabetes

- Lifestyle factors diabetic diet. Note diabetics with CKD have a VERY restrictive diet. Often difficult to adhere to
- Aim HbA₁c <6%
- Caution with agents in CKD, including Metformin (GI sx and lactic acidosis) and SGLT2 inhibitors
- Start with oral agents; may need insulin
- If cannot achieve targets, refer
- Remember cardio- and reno-protection with SGLT2, but not a first line agent

Modifying renal risk – smoking

- The most common modifiable risk factor for CVD/CKD in PLWHIV worldwide
- Smoking history, vaping history important
- Previous attempts at quitting
- One of the most important motivators to stop smoking is persistent, repeated and systematic medical advice
- Quitline, smoking cessation aids, vaping.

Varenicline (champix)



- PLWHIV France 2018
- Effective at increasing abstinence rates, although still a high rate continued to smoke (18% vs. 7%)
- Few side effects

Mercie et al, Lancet HIV 2018-03-01

Modifying renal risk – Medications

- Consider medications in CKD, both nephrotoxicity and correct doses
- Nephrotoxic medications: stop NSAIDs, and specific advice to avoid them, including topical preparations.
- ART esp. TDF
- Remember renal effects of COBI and Dolutegravir: changes eGFR not aGFR.

Case – progress

- Continued non-adherence
- Went back to the Philippines for 3 months to find her teenage son, missing in the jungle, no Rx
- Severe hypertension, viraemia
- Attempts at engagement not very successful
- Worried about other co-morbidities
- Unfortunately, continued deterioration in eGFR, about to start dialysis. ? Suitable for transplantation

A sad downwards spiral



Multiple comorbidities

- Addressing each can be time-consuming
- Need a comprehensive approach, often in conjunction with multiple specialists
- Interactions and poly-pharmacy
- Lifestyle factors just as important as medications, perhaps more so
- Danger of therapeutic nihilism
- "my blood pressure is always better than that on my home machine"

When to refer: CKD

- Complex patients at high risk of kidney disease, multiple comorbidities. Shared care, sometimes with cardiologists, diabetes centre, dietician etc.
- Difficult to control hypertension
- Unexplained haematuria
- Proteinuria >1g/day
- eGFR< 60 <u>OR</u> rapid loss of renal function (~10-20%p.a.)
- Advanced CKD eGFR< 30 or rapid loss of function urgent
- AKI
- Concerns regarding ART/nephrotoxicity

Questions?